Thursday 30 June 2016

The Growing Prospects for Cord Blood Banking in Stem Cell Therapies

There is a high potential to cure certain dangerous diseases with help of cord blood and tissue. These conditions relate to immune and blood system, sometimes involving bones and muscles. Cord blood preservation is handled by both public and private banks, where one can even do donations. According to the stem cell market research report, cord blood as a search term on search engines is very costing, and a click can cost US$20-40.

But, given the advantage that cord blood serves needs of donor’s family and donor, many are opting to stem cell and cord blood storage option. As per the healthcare research reports, automated cord blood processing is picking up heat, and other new technologies are reducing cost to storage. Public awareness programs are rising, and this is helping people to acquaint with the benefits of the treatments for worst of the diseases, which are otherwise terminal and find rare cures only.

How has the Industry Grown Steadily?

The first company to bring cord blood storage was in 1995, and then Asian and U.S nations entered in the market to bring a great upsurge in competition. In few areas private industry intervention in this market segment is not allowed. Some of the top investors in the cord blood banking industry are Bay City Capital, GTCR, LLC, KKR & Company, and ABS Capital Partners & HLM Management.

From the past few years, the industry has progressed with advanced techniques of storing cord blood and stem cells. There is an increasing growth opportunities in clinical trials for the system in connecting with stem cell applications for mesenchymal and hematopoietic.  The report expresses inter-regional collaborations, demand diversification for amniotic fluid, stem cells, placental tissues, and relative therapies.

What are the Key Obstructions to the Market?

The industry also faces some challenges like fourfold increase in expenditure on the banks functioning; new accreditation statutes, low turnover rate, difficulty updating ancillary staff and obstetrician, and low acceptance of the therapies are some factors that restrict expansion. In the cord blood banking market, the transplant processes can range anywhere between US$200,000-300,000 on a single treatment. There is also poor press coverage for the services, which is again a reason of slow progress.

No comments:

Post a Comment